Valeant Pharmaceuticals Intl Inc


4 Reasons to Stay Away from Valeant Pharmaceuticals Intl Inc

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is a risky play for even the most confident investor. Share prices gave a glimmer of hope recently …

Valeant Pharmaceuticals Intl Inc Faces Uncertain Future, Endo Not the Most Attractive Near-Term Stock

Valeant Still Has Higher Risk Profile Despite ‘Solid’ Q2 Results Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares crashed 10% yesterday after the troubled biotech …

Paulson Reduces Holdings of Valeant Pharmaceuticals Intl Inc (VRX) Due to Required Rebalancing of Portfolio

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) confirms that Paulson & Co., Inc.

Valeant Pharmaceuticals Intl Inc Not Quite Through the Woods Yet, Kite Pharma Vaulting to Green Light

Valeant’s Strengths Are Laced with Challenges Valeant Pharmaceuticals Intl Inc (NYSE:VRX) delivered a sound second-quarter print yesterday before the bell- but the troubled …

Mizuho Still Not Expecting a Turnaround for Valeant Pharmaceuticals Intl Inc (VRX), Neutral on Depomed (DEPO)

Mizuho analyst Irina Rivkind Koffler came out today with new research notes on a handful of biotechnology stocks. Let’s take a look and …

All Eyes on Valeant Pharmaceuticals Intl Inc (VRX) Earnings, Bedlam for Teva Pharmaceutical (TEVA)

Valeant’s a Deep Shade of Grey All eyes are on Valeant Pharmaceuticals Intl Inc (NYSE:VRX) as the Street wonders if this troubled biotech …

Looking Ahead of Wall Street: Valeant Pharmaceuticals Intl Inc (VRX), NVIDIA Corporation (NVDA), Snap (SNAP)

Valeant Pharmaceuticals Intl Inc Valeant (NYSE:VRX) is due to report its earnings results for the second quarter this morning. FactSet consensus reveals that …

Valeant Pharmaceuticals Intl Inc: FDA Issues Complete Response Letter on Latanoprostene Bunod Ophthalmic Solution, 0.024% NDA

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) announced it has received a Complete Response Letter (CRL) from the FDA regarding the New Drug Application (NDA) …

Valeant Pharmaceuticals Intl Inc (VRX) Could Be A Short-Term Bear Trap, Dynavax Technologies Corporation (DVAX) Heplisav Boasts Same Commercial Potential Despite PDUFA Push-back

Valeant May Post Weak 2Q Print- But Might Not Dent Investor Sentiment After All Valeant Pharmaceuticals Intl Inc (NYSE:VRX) delivers its second-quarter print …

These Analysts Say It’s Not Time to Buy Teva Pharmaceutical Industries Ltd (ADR) (TEVA) and Valeant Pharmaceuticals Intl Inc (VRX)

Is Teva Pharmaceutical a Falling Knife to Catch After Plunging over 30%? This week turned out to be a nightmare for shareholders of Teva …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts